Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Blood (2024) 144 (23): 2375–2388.

https://doi.org/10.1182/blood.2023023616

Published: 2024

Includes: Supplemental data

Journal Articles

Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3 -ITD-Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

David Martinez-Cuadron, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Jose Antonio Pérez-Simón, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, Claudia Sargas, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Júlia Morán Sánchez, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordonez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, Jorge Labrador, Pau Montesinos

Blood (2024) 144 (Supplement 1): 2895.

https://doi.org/10.1182/blood-2024-205064

Published: 2024

Journal Articles

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

Pau Montesinos, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Eduardo Rodriguez Arboli, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Jose Ángel Raposo Puglia, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordoñez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, David Martinez-Cuadron, Jorge Labrador

Blood (2024) 144 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2024-204779

Published: 2024

Journal Articles

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Ajai Chari, Albert Oriol, Amrita Krishnan, Maria Del Carmen Martinez Chamorro, Luciano Costa, Maria Victoria Mateos, Monique C Minnema, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, M. Damiette Smit, Swarna Ramanjulu, Paula Rodríguez Otero

Blood (2023) 142 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2023-181228

Published: 2023

Journal Articles

Acute and Post-Acute COVID-19 Severity and Mortality in Patients with Hematologic Malignancies: A Population-Based Registry Study

Blood (2021) 138 (Supplement 1): 186.

https://doi.org/10.1182/blood-2021-152539

Published: 2021

Journal Articles

Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience

Blood (2021) 138 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2021-151267

Published: 2021

Journal Articles

Impact of Sars-Cov-2 Infection in Hematopoietic Transplant Patients: Experience from the Madrid Group

Rebeca Bailén, MD, Mi Kwon, MD PhD, Beatriz Aguado, MD, Rafael F. Duarte, MD PhD FRCP, Maria Calbacho, MD, Anabelle Chinea, MD, Pilar Llamas, MDPhD, Rosalía Riaza Grau, Jose Angel Hernandez-Rivas, MD PhD, Victor Jimenez Yuste, MD PhD, Carmen Martínez-Chamorro, MD, F. Javier Penalver, MD, Ataulfo González, MD, Juan F del Campo, Keina Quiroz, MD, Gillen Oarbeascoa, MD, Julio Garcia Suarez, José Luis Díez-Martín, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-138728

Published: 2020

Journal Articles

Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry

Blood (2015) 126 (23): 4231.

https://doi.org/10.1182/blood.V126.23.4231.4231

Published: 2015

Journal Articles

Bendamustine In Combination With Rituximab As First-Line Treatment For Indolent Non-Hodgkin Lymphoma: Retrospective Analysis Of An Spanish Registry

Silvia Solorzano, Carmen Martinez-Chamorro, Carlos Panizo, Cristina Quero, Guillermo Deben, MD, Jose Paz, Ana Batlle, MD, Alfons Serrano, Zayda Muentes, Antonio Gutierrez, MD, PhD, Jose Francisco Tomas, MD

Blood (2013) 122 (21): 5094.

https://doi.org/10.1182/blood.V122.21.5094.5094

Published: 2013

NARROW

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3 -ITD-Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Acute and Post-Acute COVID-19 Severity and Mortality in Patients with Hematologic Malignancies: A Population-Based Registry Study

Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience

Impact of Sars-Cov-2 Infection in Hematopoietic Transplant Patients: Experience from the Madrid Group

Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry

Bendamustine In Combination With Rituximab As First-Line Treatment For Indolent Non-Hodgkin Lymphoma: Retrospective Analysis Of An Spanish Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only